Side Menu
 
Medicrea | Investors
3588
page-template-default,page,page-id-3588,page-child,parent-pageid-3590,customer-area-active,ajax_fade,page_not_loaded,smooth_scroll,

Investors

About Medicrea

 

MEDICREA specializes in bringing pre-operative digital planning and pre and post-operative analytical services to the world of complex spine. Through the lens of predictive medicine, MEDICREA leads the design, integrated manufacture, and distribution of 30+ FDA approved implant technologies, utilized in over 100k spinal surgeries to date. Operating in a $10 billion marketplace, MEDICREA is an SME with 150 employees worldwide, which includes 55 at its USA Corp. subsidiary in NYC. The Company has an ultra-modern manufacturing facility in Lyon, France housing the development and production of 3D-printed titanium patient-specific implants.

By leveraging its proprietary software analysis tools with big data and deep learning technologies supported by an expansive collection of clinical and scientific data, MEDICREA is well-placed to streamline the efficiency of spinal care, reducing procedural complications and limiting time spent in the O.R.

Events December 15, 2016. KOL Investor Meeting at 08:00 EST. Contact Investor Relations for more information. Join webcast.
IR ContactFabrice Kilfiger
Chief Financial Officer
fkilfiger@medicrea.com
Tel: +33 (0)4 72 01 87 87

 

 

 

 

Overview

MEDICREA adopted the International Reporting and Financial Standards (IFRS) for the first time in 2009. MEDICREA’s financial statements are since then compliant with IFRS in conformity with the european law referenced 1606/2002 and dated the 19th of July 2002

ipqd6cotqtion

Board of directors

Denys SOURNAC, Chairman of the Board of Directors and Chief Executive Officer Co-founder of MEDICREA

Mr Sournac comes from a purely scientific and medical background. With over 30 years’ experience in orthopaedics, notably in the retail of orthopaedic supplies. Denys Sournac was the man behind the 2002 merger of MEDICREA Technologies and ORSCO International, which gave rise to the MEDICREA Group in its current form. Mission: To expand MEDICREA, hold responsibility for the organisation and management of the Group and define its global strategy.

Richard KIENZLE, Chief Commercial and Business Development Officer

Mr Richard Kienzle, also known as Rick, has been Chief Commercial & Business Development Officer at Medicrea since August 2016. Mr Kienzle is a successful spine executive with a deep network in the World-Wide Spine Markets. He is a Founder and served as the Executive Vice President Global Sales and Marketing of Globus Medical, Inc. (Ticker symbol GMED) from 2003 to 2011. His responsibilities included all global sales, marketing, training and commercial functions of Globus including the development of an exclusive national distribution network. During Mr Kienzle’s tenure, Globus was widely noted as the fastest growing company in orthopedic history. GMED closed a $110M private placement with Goldman Sachs and Clarus Ventures in 2007 and an IPO with Goldman and BOA in 2012. Prior to Globus, he served for 5 years as Area Vice President; Synthes Spine where he was responsible for all sales and marketing functions at this top-performing enterprise with over $90M in annual revenue (30% compounded growth rate). Mr Kienzle’s experience also includes 8 prior years with United States Surgical Corp working side-by-side in the OR with surgeons of all surgical specialties, followed by a series of promotions and culminating as the National Business Director. He has additional experience in the banking field working for The Equitable Financial Companies and Mellon Bank. He has been a Director at Medicrea since August 2016. Mr Kienzle received his Bachelor of Arts from Denison University. Mission: to oversee the commercial expansion of Medicrea’s patient-specific UNiD technology and personalized treatment modalities.

Jean-Philippe CAFFIERO, Deputy Chief Executive Officer

Co-founder of MEDICREA. Over 30 years’ experience in orthopaedics, particularly in Asia. Mission: to expand and coordinate the international distribution network.

Marc RECTON, independent director

After working for Union Financière de France and Compagnie France Finance Patrimoine, in 1990 Marc Recton founded Marc Recton & Associés, an independent financial advisory company and a member of the Chambre des Indépendants du Patrimoine (an independent professional body for financial advisors). Marc Recton is registered with the AMF as a Financial Investment Consultant. In 2003, Marc also founded ALAMA FINANCE, which specializes in investments in non-listed companies and in financial engineering for overseas companies. Marc RECTON has been a member of the MEDICREA Board of Directors since 2003.

Christophe BONNET, independent director

A graduate of the Ecole de Management de Lyon, Christophe founded ORSCO INTERNATIONAL, which is now MEDICREA INTERNATIONAL. Christophe BONNET has spent the last 12 years working in strategy and management consulting. After previously working for Bossard Consultant, he is currently Secretary General and a partner of Kea & Partners consultants in Paris. Christophe BONNET has been a member of the MEDICREA Board of Directors since 2002.

Jean Joseph MORENO, independent director

Behind the creation of a number of industrial companies in France (industrial, boilerwork and mechanical complexes), service companies and stores, Jean Joseph MORENO has also founded companies overseas, notably in Guinea, Cameroon, Senegal, Côte d’Ivoire and Iran. Jean-Joseph Moreno has also, during his professional career, held major positions on various bodies, including President of the Rhone branch of CGPME-URPMI and Vice-President of the national UTPMI-CGPME, Vice-President of CCI de Lyon and Vice-President of Expora, Member of the Rhône-Alpes Economic and Social Council and Director and Deputy Vice-President of Olympique Lyonnais, Jean-Joseph MORENO has been a member of the MEDICREA Board of Directors since 2002

Patrick BERTRAND, independent director

A graduate of France’s elite Polytechnique engineering school, Patrick BERTRAND spend 22 years working for the Crédit Lyonnais group, where he was notably in charge of the Rhône Alpes Auvergne region, and then became Chairman of the Mescatiss group, which specializes in the fire-risk aspect of nuclear safety. Patrick BERTRAND currently devotes himself to running the Euro PJB group, a holding company in which he is a majority shareholder and a company that works in agricultural activities and industrial venture capital. Patrick BERTRAND has been a member of the MEDICREA Board of Directors since 2002.

François-Régis ORY, independent director

With a PhD in Pharmacy, and a former intern at Hôpitaux de Lyon, François-Régis ORY was Scientific and Technical Director at SOFRADIM, which specializes in surgical implants, before taking the helm of this company in 1996 through an LBO. François-Régis ORY then grouped together SOFRADIM’s production and distribution activities within a holding company he named Floréane Medical Implants, for which he instigated an IPO in June 1998. Specializing in the design, development and distribution of innovative reinforcement surgical implants for parietal, vascular, urologic and gynecological surgery, leader on its market, Floréane Medical Implants was sold to the Tyco International Ltd. group in 2005. François-Régis ORY has been a member of the MEDICREA Board of Directors since 2002.

Pierre BUREL, independent director

Pierre BUREL began his career as an entrepreneur by setting up BUREL TRAVAUX, a company involved mainly in electrical engineering and telecommunications. At the same time, he also worked in the hotel sector. As from 1968, he was involved in the expansion of MEDICA France, a group of healthcare institutions which had 30 centers and 3,000 beds when it was sold in 2000. Pierre BUREL currently manages wineries. Pierre BUREL was a director of MEDICREA INTERNATIONAL SA from 2002 to 2006, then a non-voting advisor from 2011 to 2014, before being
reappointed as a director.

[/accordion]

Management

DS_website

Denys SOURNAC

Chairman of the Board of Directors and Chief Executive Officer
Co-founder of MEDICREA

Mr Sournac comes from a purely scientific and medical background. With over 30 years’ experience in orthopaedics, notably in the retail of orthopaedic supplies. Denys Sournac was the man behind the 2002 merger of MEDICREA Technologies and ORSCO International, which gave rise to the MEDICREA Group in its current form. Mission: To expand MEDICREA, hold responsibility for the organisation and management of the Group and define its global strategy.

kienzle_rick-1

Richard KIENZLE

Chief Commercial and Business Development Officer

A successful spine executive with over 25 years of experience bringing with him a deep network in the World-Wide Spine Markets, Mr Kienzle is a Founder and served as the Executive Vice President Global Sales and Marketing of Globus Medical, Inc. (Ticker symbol GMED) until 2011. During Mr Kienzle’s tenure, Globus was widely noted as the fastest growing company in orthopedic history. GMED closed a $110M private placement with Goldman Sachs and Clarus Ventures in 2007 and an IPO with Goldman and BOA in 2012. Prior to Globus, he held the position of Area Vice President at Synthes Spine where he was responsible for all sales and marketing functions at this top-performing enterprise with over $90M in annual revenue (30% compounded growth rate) and before that culminated his 8 years with United States Surgical Corp as the National Business Director. Mission: to oversee the commercial expansion of Medicrea’s patient-specific UNiD technology and personalized treatment modalities.

Pierre OLIVIER

CEO
MEDICREA USA

25 years’ experience in project management, mainly in the United States, particularly in sales launches of new innovative products. Mission: Expansion of MEDICREA USA, overall management of US operations with the goal of achieving profitable growth.

Fabrice KILFIGER

Finance
CFO

Educational background in management and finance. 25 years’ experience in finance, including over 10 years heading the finance divisions of listed companies. Mission: Financial management of the Group, coordination of finance teams within subsidiaries, in charge of relations with banks and market authorities, responsible for financial information released to market.

David RYAN

VP Product Development
and Marketing

Studied biomaterials and biomechanics at the Université de Technologie de Compiègne (UTC) Former R&D Director, Scient’x. 11 years’ experience in orthopaedics. Mission: To design, develop and monitor products in close association with opinion-leading surgeons. To conduct clinical studies.


Financial information
Name Size
Press Releases
Name Size
SUBSCRIBE TO NEWSLETTER
Macbook Pro
* Intel Core i7 (3.8GHz, 6MB cache)
* Retina Display (2880 x 1880 px)
* NVIDIA GeForce GT 750M (Iris)
* 802.11ac Wi-Fi and Bluetooth 4.0
* Thunderbolt 2 (up to 20Gb/s)
* Faster All-Flash Storage (X1)
* Long Lasting Battery (9 hours)
Vous accédez maintenant au domaine réservé aux professionnels de la santé du site internet Medicrea.